AgingResearch.NewsJoin free

Phase 3Active, not recruiting

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Sponsor
Eli Lilly and Company (Industry)
Enrollment
1,250 planned
Conditions
Diabetes Mellitus, Type 2
Interventions
Retatrutide; Semaglutide
Ages
adults, older adults
Registry
NCT06260722

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.

Primary outcomes

  • Change from Baseline in Hemoglobin A1c (HbA1c) (%)

History

  1. Study completion expected

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered

In the news

TrialsSTAT+ (opens STAT in a new tab, subscription)

Eli Lilly says retatrutide lowers blood sugar and weight more than Ozempic in diabetes

The large head-to-head study tested Lilly’s investigational incretin injection against Novo Nordisk’s drug.

Also in Endpoints News (opens Endpoints News in a new tab), BioPharma Dive (opens BioPharma Dive in a new tab), ByDrug (opens ByDrug in a new tab), Diario Médico (opens Diario Médico in a new tab), asiae.co.kr (opens asiae.co.kr in a new tab), oe24 (opens oe24 in a new tab)